At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

Hannah who lives with Vanishing White Matter Disease has formed a blossoming friendship with Marie Curie Volunteer Companion ...

Immutep’s efti with radiotherapy and pembrolizumab meets primary endpoint in phase II trials for soft tissue sarcoma ...